

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

May 11, 2026

Consolidated Financial Results for the Fiscal Year Ended March 31, 2026 (Under IFRS)

Company name: YUKIGUNI FACTORY CO., LTD.
 Listing: Tokyo Stock Exchange
 Securities code: 1375
 URL: <https://www.yukiguni-factory.co.jp/>
 Representative: Masafumi Yuzawa, President and CEO, Representative Director
 Inquiries: Masayoshi Yoneyama, Corporate Planning Division, General Manager, IR & Public Relations Department
 Telephone: +81-25-778-0162
 Scheduled date of annual general meeting of shareholders: June 26, 2026
 Scheduled date to commence dividends payment: June 8, 2026
 Scheduled date to file annual securities report: June 25, 2026
 Preparation of supplementary material on financial results: Yes
 Holding of financial results briefing: Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated Financial Results for the Fiscal year Ended March 31, 2026 (from April 1, 2025 to March 31, 2026)

(1) Consolidated Operating Results

(Percentages indicate year-on-year changes.)

Fiscal year ended	Total income		Operating profit		Profit before tax		Profit	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
March 31, 2026	53,449	0.6	4,319	78.5	4,195	92.9	2,954	97.5
March 31, 2025	53,139	11.9	2,419	-13.6	2,175	-2.4	1,496	10.2

Fiscal year ended	Profit attributable to owners of parent		Total comprehensive income		Basic earnings per share	Diluted earnings per share
	Millions of yen	%	Millions of yen	%	Yen	Yen
March 31, 2026	2,958	96.9	2,904	104.2	74.18	74.18
March 31, 2025	1,502	11.2	1,422	4.5	37.66	37.65

Fiscal year ended	Return on equity attributable to owners of parent	Ratio of profit before tax to total assets	Ratio of operating profit to total income
	%	%	%
March 31, 2026	21.8	11.1	8.1
March 31, 2025	12.6	5.7	4.6

(Reference)

Fiscal year ended	Revenue		Core operating profit		Core EBITDA		Core EBITDA margin
	Millions of yen	%	Millions of yen	%	Millions of yen	%	%
March 31, 2026	37,845	2.0	4,139	7.3	6,422	3.7	17.0
March 31, 2025	37,102	10.9	3,858	50.3	6,196	29.0	16.7

(2) Consolidated Financial Position

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent to total assets	Equity attributable to owners of parent per share
As of	Millions of yen	Millions of yen	Millions of yen	%	Yen
March 31, 2026	37,686	14,770	14,770	39.2	370.43
March 31, 2025	37,868	12,525	12,366	32.7	309.98

(3) Consolidated cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
Fiscal year ended	Millions of yen	Millions of yen	Millions of yen	Millions of yen
March 31, 2026	4,534	-2,085	-2,406	3,968
March 31, 2025	5,519	-2,252	-2,159	3,903

2. Cash Dividends

	Annual dividends per share					Total cash dividends (Total)	Payout ratio (Consolidated)	Ratio of dividends to equity attributable to owners of parent (Consolidated)
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total			
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
Fiscal year ended March 31, 2025	-	3.00	-	12.00	15.00	598	39.8	5.0
Fiscal year ended March 31, 2026	-	4.00	-	19.00	23.00	917	31.0	6.8
Fiscal year ending March 31, 2027 (Forecast)	-	5.00	-	15.00	20.00		31.4	

Note: The year-end dividend per share for the fiscal year ended March 31, 2026 has been changed from ¥12.00 to ¥19.00. For details, please refer to the “Variances Between Consolidated Financial Forecasts and Actual Results, Year-on-Year Changes in Non-Consolidated Results and Cash Dividend of Surplus (Increased)” released today (May 11, 2026).

3. Forecast of Consolidated Financial Results for the Fiscal Year Ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

(Percentages indicate year-on-year changes.)

	Total income		Operating profit		Profit before tax		Profit	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Full year	56,910	6.5	4,140	-4.1	3,950	-5.8	2,540	-14.0

	Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Yen
Full year	2,540	-14.1	63.69

(Reference)

	Revenue		Core Operating Profit		Core EBITDA		Core EBITDA Margin
	Millions of yen	%	Millions of yen	%	Millions of yen	%	%
Full year	39,640	4.7	3,960	-4.3	6,450	0.4	16.3

*** Notes**

(1) Significant changes in the scope of consolidation during the period: None

(2) Changes in accounting policies and changes in accounting estimates

- (i) Changes in accounting policies required by IFRS: None
- (ii) Changes in accounting policies due to other reasons: None
- (iii) Changes in accounting estimates: None

(3) Number of issued shares (ordinary shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of March 31, 2026	39,910,700 shares
As of March 31, 2025	39,910,700 shares

(ii) Number of treasury shares at the end of the period

As of March 31, 2026	27,878 shares
As of March 31, 2025	6,666 shares

(iii) Average number of shares outstanding during the period

Fiscal year ended March 31, 2026	39,876,045 shares
Fiscal year ended March 31, 2025	39,891,696 shares

[Reference] Overview of non-consolidated financial results

1. Non-consolidated financial results for the fiscal year ended March 31, 2026 (from April 1, 2025 to March 31, 2026)

(1) Non-consolidated operating results

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Net income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Fiscal year ended								
March 31, 2026	35,372	2.6	2,803	15.5	2,875	29.0	1,568	-
March 31, 2025	34,486	6.4	2,427	177.5	2,229	244.6	-3	-

	Basic earnings per share	Diluted earnings per share
Fiscal year ended	Yen	Yen
March 31, 2026	39.34	39.34
March 31, 2025	-0.08	-0.08

(2) Non-consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	Yen
March 31, 2026	46,872	25,449	54.3	638.11
March 31, 2025	48,345	24,542	50.8	615.03

Reference: Equity

As of March 31, 2026: ¥25,449 million
As of March 31, 2025: ¥24,542 million

*Financial results reports are exempt from review conducted by certified public accountants or an audit firm.

*** Proper use of earnings forecasts, and other special matters**

(Caution concerning forward-looking statements)

The forward-looking statements, such as forecasts of financial results, included in this document are based on information available to the management as of the date of the document and certain assumptions that the management considers reasonable. The Company does not promise that forecasts will be achieved. Actual results may differ significantly due to a range of factors.

(Other special comments)

- (1) The Company and its consolidated subsidiaries (together, “the Group”) apply the International Financial Reporting Standards (hereinafter “IFRS”).
- (2) Core operating profit = Operating profit – IAS41 “Agriculture” applying effects – Other income and expenses – One-time income and expenses
- (3) Core EBITDA = Core operating profit + Depreciation + Amortization
- (4) Core EBITDA margin = Core EBITDA / Revenue
- (5) The effect of applying IAS 41 “Agriculture” is to apply IAS 41 “Agriculture” to the production process of mushrooms, from preparation to harvest, and to measure the mushrooms as biological assets at fair value less costs to sell. The gains or losses from the changes in fair value are considered as the impact amount.
- (6) Other income and expenses are mainly impairment loss and loss on disposal of fixed assets.
- (7) One-time income and expenses are income and expenses that are not incurred in the normal course of business. There are no one-time income and expenses incurred during the Fiscal year ended March 31, 2025 and the Fiscal year ended March 31, 2026.
- (8) Core operating profit, Core EBITDA and Core EBITDA margin are not indicators defined by IFRS, but the Group assumes these indicators are useful for investors to evaluate the Group’s performance. These financial indicators exclude the effect of non-recurring gains / losses and items that do not adequately present the Group’s performance relative to its competitors. Core operating profit, Core EBITDA, Core EBITDA margin should not be considered as indicators to replace the other indicators shown in accordance with IFRS because they do not include some of the items that affect the profit for the period, so they are subject to significant restrictions as means of analysis. Core operating profit, Core EBITDA, Core EBITDA margin disclosed by the Group may be less useful in comparison with the same or similar indicators of other competitors because they are calculated according to a different method from those of such other companies.

(How to obtain supplementary financial results briefing materials and financial results briefing details)

Supplementary financial results briefing materials are posted both on TDnet and our website on May 11, 2026. A presentation for institutional investors and analysts is scheduled to be held on, May 21, 2026 in a hybrid format of on-site and webcast.

Accompanying Materials – Contents

I. Qualitative Information for the Fiscal Year Ended March 31, 2026.....	2
1. Analysis of Operating Results.....	2
2. Analysis of Financial Position.....	4
3. Analysis of Cash Flows	4
4. Explanations about Forward-Looking Information Including Forecast of Consolidated Financial Results...5	
II. Basic Policy Regarding Selection of Accounting Standards.....	6
III. Consolidated Financial Statements and Significant Notes.....	7
1. Consolidated Statements of Financial Position.....	7
2. Consolidated Statements of Income and Comprehensive Income	9
3. Consolidated Statement of Changes in Equity.....	11
4. Consolidated Statements of Cash Flows.....	12
5. Notes to Summarized Quarterly Consolidated Financial Statements.....	13
(Going Concern Assumptions)	13
(Segment Information)	13
(Earnings per Share)	14
(Significant Subsequent Events)	14

I. Qualitative Information for the Fiscal Year Ended March 31, 2026

1. Analysis of Operating Results

During the consolidated fiscal year under review, the prolonged rise in prices and exchange rate fluctuations continued to strain household finances in Japan, although the employment and income environment continued to improve. In addition, the economic outlook remains uncertain due to prolonged geopolitical risks, tensions in the Middle East, trends in U.S. trade policy, and volatility in financial and capital markets.

In this economic environment, the Group recognizes that securing medium- to long-term growth and strengthening its business foundation are becoming even more important. As part of its initiatives, the Group changed its organizational structure effective November 1, 2025. This reorganization is intended to strengthen the research & development function for mid- to long-term growth based on the Medium-Term Business Plan announced in December 2023. Specifically, the former "Research & Development Office" has been expanded to the "Research & Development Division", placing it on the same level as other divisions to optimize the allocation of management resources and strengthen company-wide collaboration. In addition, the Group has established the "KINOKO Research Institute" to deepen current mushroom research & development, and the "MIRAI Research Institute" to take charge of research & development on functional materials and new technologies. Our aim is to enhance expertise in our research domains and strengthen our research and development structure.

The Group will continue to steadily promote research and development centered on mushrooms in order to create new technologies and products, thereby adding greater value and pursuing sustainable growth.

Total income for the current consolidated cumulative period was ¥53,449 million (+0.6% year-on-year), of which revenue was ¥37,845 million (+2.0% year-on-year), operating profit was ¥4,319 million (+78.5% year-on-year), profit attributable to owners of parent was ¥2,958 million (+96.9% year-on-year). The increase in operating profit and net income is primarily due to a rebound from impairment losses recognized in the previous fiscal year.

In the current consolidated cumulative period, gains arising from changes in fair value related to the application of IFRS Agricultural Accounting (IAS 41) were included in total income of ¥15,604 million (-2.7% year-on-year) and in the cost of sales of ¥15,532 million (-1.4% year-on-year).

[Business results for the Fiscal year ended March 31, 2026]

	Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026	(Millions of yen) % Change year-on-year
Revenue	37,102	37,845	2.0
Gains arising from changes in fair value	16,037	15,604	(2.7)
Total income	53,139	53,449	0.6
Operating profit	2,419	4,319	78.5
Profit before tax	2,175	4,195	92.9
Profit attributable to owners of parent	1,502	2,958	96.9

The status of revenue by business segment during the current consolidated fiscal year is as follows.

[Mushroom business]

1) Maitake

With the change of our corporate name, we have redesigned our product packaging and are expanding our lineup of newly designed products that offer convenience with larger cuts and great value, leveraging our strength in our extensive product lineup. We are striving to offer a wide range of products and sales promotion plans that accurately capture the needs of consumers, with the aim of increasing our market share and strengthening our premium brand strategy. In addition, we are promoting further

demand expansion through sales floor displays and cooking menu suggestions tailored to seasonal events.

Unit sales prices decreased, but sales volume increased those compared to the same period of the previous year. Thus, revenue of the Maitake business was ¥20,264 million (+1.0% year-on-year).

2) Eryngii

We offer a wide variety of standard products in variety of sizes, from small packs to large packs, and we are working to develop products that meet a wide range of customer needs—such as convenient pre-cut Eryngii mushroom products and products sold by weight—with the aim of expanding demand.

Sales volume and unit sales prices exceeded those compared to the same period of the previous year. Thus, revenue of the Eryngii business was ¥3,973 million (+3.9% year-on-year).

3) Buna-shimeji

We are developing sales strategies centered on 1-root products, promoting stable pricing, closely monitoring the fruit and vegetable market and its market trends, and flexibly introducing products such as 2-root products in different quantities according to supply and demand balance.

Sales volume and unit sales prices exceeded those compared to the same period of the previous year. Thus, revenue from the Buna-shimeji business was ¥7,948 million (+5.1% year-on-year).

4) Other mushrooms

As for button mushrooms, the Company is focusing on stabilizing production conditions continuously and implementing sales promotion plans to strengthen sales and create new demand, however, revenue of button mushrooms remained sluggish compared to the same period of the previous year. In addition, revenue of Hatake-shimeji and Hon-shimeji remained sluggish, but exotic mushrooms handled by our overseas group company remained strong compared to the same period of the previous year. As a result of the above, revenue from other mushroom businesses was ¥5,284 million (-1.0% year-on-year).

[Other]

Other revenue is mainly derived from sales of health foods, the substrate activator and the new Mushroom Meat series of products which was launched in February 2025. Revenue of substrate activator and health foods remained strong during the current consolidated fiscal year. In addition, the Company is working to increase product awareness for the Mushroom Meat and strengthen sales through aggressive promotional measures. As a result, revenue from other businesses was ¥373 million (+15.9% year-on-year)

Revenue by business segment is as follows.

	(Millions of yen)		
	Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026	% Change year-on-year
Mushroom business	36,779	37,471	1.9
Maitake	20,055	20,264	1.0
Eryngii	3,822	3,973	3.9
Buna-shimeji	7,563	7,948	5.1
Other mushrooms	5,337	5,284	(1.0)
Other	322	373	15.9
Total Revenue	37,102	37,845	2.0

2. Analysis of Financial Position

[Assets]

Total assets at the end of the current consolidated fiscal year (as of March 31, 2026) were ¥37,686 million (-¥182 million from the end of the previous consolidated fiscal year). Current assets were ¥11,688 million (+¥187 million from the end of the previous consolidated fiscal year). This was mainly due to increases of ¥189 million in trade and other receivables, ¥158 million in biological assets and ¥126 million in other current assets, while a decrease of ¥354 million in inventories. Non-current assets were ¥25,997 million (-¥369 million from the end of the previous consolidated fiscal year). This was mainly due to decreases of ¥190 million in deferred tax assets and ¥148 million in retirement benefit asset.

[Liabilities]

Total liabilities at the end of the current consolidated fiscal year were ¥22,916 million (-¥2,426 million from the end of the previous consolidated fiscal year). Current liabilities were ¥11,467 million (+¥1,965 million from the end of the previous consolidated fiscal year). This was mainly due to an increase of ¥3,000 million in current portion of long-term borrowings, while decreases of ¥489 million in income taxes payable, ¥256 million in employee benefit accruals and ¥159 million in trade and other payables. Non-current liabilities were ¥11,448 million (-¥4,392 million from the end of the previous consolidated fiscal year). This was mainly due to a decrease of ¥4,422 million in borrowings as a result of scheduled repayments, resulting from scheduled repayments as well as the reclassification of a portion of long-term borrowings to current liabilities.

[Equity]

Total equity at the end of the current consolidated fiscal year were ¥14,770 million (+¥2,244 million from the end of the previous consolidated fiscal year). This was mainly due to an increase of ¥2,212 million in retained earnings resulting from the recording of ¥2,958 million in profit attributable to owners of the parent and the payment of ¥638 million in dividends from surplus.

3. Analysis of Cash Flows

The balance of cash and cash equivalents at the end of the current consolidated fiscal year increased by ¥65 million from the end of the previous consolidated fiscal year to ¥3,968 million. The status of each cash flow and their factors are as follows:

[Net cash flows from operating activities]

Funds provided as a result of operating activities was ¥4,534 million (the amount provided was ¥5,519 million in the same period of the previous year). This was mainly due to profit before tax of ¥4,195 million, depreciation and amortization of ¥2,292 million, a decrease of ¥361 million in inventories, while income taxes paid of ¥1,519 million, decreases of ¥355 million in trade and other payables and ¥256 million in employee benefit liabilities.

[Net cash flows from investing activities]

Funds used as a result of investing activities were ¥2,085 million (the amount used was ¥2,252 million in the same period of the previous year). This was mainly due to the expenditure of ¥2,095 million for the acquisition of expanded and renewed property, plant and equipment.

[Net cash flows from financing activities]

Funds used as a result of financing activities were ¥2,406 million (the amount used was ¥2,159 million in the same period of the previous year). This was mainly due to repayments of long-term borrowings of ¥1,431 million, dividends paid of ¥638 million and repayments of lease liabilities ¥234 million.

4. Explanations about Forward-Looking Information Including Forecast of Consolidated Financial Results

1) Outlook for the Group as a whole

The environment surrounding the Group is characterized by the declining birthrate and aging population in Japan, which continues to drive a shrinking trend in the overall food market. In addition, the declining domestic workforce is making it even more difficult to secure labor, which is a challenge caused by social structural factors. Also, factors that increase costs, such as soaring material costs and rising logistics costs,

continue to exert pressure on corporate activities. Moreover, the outlook remains uncertain due to a combination of factors such as the tense situation in the Middle East and exchange rate trends.

In this environment, for the fiscal year ending March 31, 2027, the Group expects procurement costs to remain high, and in light of changes in the external environment, including the situation in the Middle East and exchange rate trends, anticipates a certain degree of uncertainty in terms of profits. Therefore, the Group recognizes the importance of steadily implementing measures to achieve the Medium-Term Business Plan, such as optimizing the allocation of management resources and strengthening the company's structure through improved operational efficiency.

Based on the Medium-Term Business Plan, the Group aims to create new value and achieve sustainable growth by maintaining and strengthening profitability and steadily developing its business foundations, even in a difficult environment, while leveraging the technologies and knowledge it has cultivated to date and pursuing the potential of mushrooms.

Based on the above, for the fiscal year ending March 31, 2027, we forecast total income of ¥56,910 million (+6.5% year-on-year), operating profit of ¥4,140 million (-4.1% year-on-year), and profit before tax of ¥3,950 million (-5.8% year-on-year), with profit attributable to owners of the parent of ¥2,540 million (-14.1% year-on-year).

2) Total income

Revenue and gains arising from changes in fair value* and their combined total are projected for each of the major mushroom products, based on current performance, market trends, and the Group's outlook on the effects of its measures.

* The “gains arising from changes in fair value” represents the gain recognized in income on the increase in value (fair value due to biological assets) of the raw mushroom products created in the course of production. Such fair value gains or losses are included in “Gains from changes in fair value”. Gains arising from changes in fair value are included in income and cost of sales. The fair value gains recorded as income are the profits included in the current period's production, and the fair value gains recorded as cost of sales are the profits included in the current period's sales, which are affected by changes in production volume, sales volume, sales prices, etc. Since the application of International Accounting Standards will result in the recording of the sum of normal sales and accrual profit in the total income, the corresponding cost of sales will also be the sum of normal cost of sales and accrual profit.

[Maitake]

In the Maitake business, while customers continue to be thrifty and selective due to successive price hikes of daily necessities, the vegetable market is expected to remain stable, and the Maitake market as a whole is expected to remain at the current level, largely unchanged from the previous year. In this environment, we will strive to expand sales by leveraging our strength, namely our extensive product lineup, and by strengthening sales promotion plans, such as product proposals and sales floor development that consistently meet customer needs. We will also propose new ways to eat Maitake mushroom by introducing various menus according to the season. We will work to expand sales by increasing our share of the retail market and cultivating new customers. In addition, through ongoing promotion activities utilizing social media and other digital media, we will work to acquire a new user base and further generate demand for maitake by making our unique "Kiwami" brand widely known to our customers. Based on the above, revenue from the Maitake segment is expected to reach ¥20,660 million (+2.0% year-on-year).

[Eryngii]

In the Eryngii segment, we will continue to implement sales measures that take advantage of our extensive product lineup, which includes not only standard varieties in various weight categories, but also highly convenient sliced products and products sold by weight. In addition, we will strengthen integration between production and sales, develop new products that meet diversifying customer needs, consolidate unprofitable items, and make other proactive improvements. Based on the above measures and market trends, we project that the Eryngii segment will generate revenue of ¥4,260 million (+7.1% year-on-year).

[Buna-shimeji]

In the Buna-Shimeji business, we will continue to target a stable supply of mainly products packaged as single root, and will assemble and propose sales measures that are easy for customers to pick up. Based on the above measures and market trends, Buna-shimeji segment revenue is expected to total ¥7,980 million (+0.4% year-on-year).

[Other mushrooms]

Other mushrooms consist mainly of our overseas group companies' revenue, Button mushroom, Honshimeji, and Hatake-shimeji. Revenue from the Other mushrooms segment is expected to be ¥6,360 million (+ 20.3% year-on-year).

Based on the above, we expect revenue to be ¥39,640 million (+4.7% year-on-year) and gains arising from changes in fair value recognized in accordance with IFRS Agricultural Accounting (IAS 41) to be ¥17,260 million (+10.6% year-on-year), respectively, and total income, which is the sum of these figures, is expected to be ¥56,910 million (+6.5% year-on-year).

3) Cost of Sales and Gross Profit

Cost of sales is forecasted in consideration of production, sales, and personnel plans, trends in raw material prices, and capital investment plans.

For the fiscal year ending March, 2027, we anticipate raising material prices and an increase in labor costs due to a tight domestic labor market. As a result, "material cost, labor cost, etc." (cost of goods sold by the Group, excluding gains arising from changes in fair value recognized in accordance with IFRS Agricultural Accounting (IAS 41)) is expected to be ¥25,060 million (+5.2% year-on-year), and gain arising from changes in fair value related to the application of IFRS Agricultural Accounting (IAS 41) is expected to be ¥17,020 million (+9.6% year-on-year), respectively. As one of the policies of the Medium-Term Business Plan, "Business Processes: Streamline all processes without sanctuary," the Company will improve business processes through company-wide BPR to realize cost reduction and promote labor saving and energy saving through new investments.

Based on the above, we forecast cost of sales of ¥42,080 million (+6.9% year-on-year) and gross profit of ¥14,820 million (+5.2% year-on-year).

4) SG&A, Other Income, Other Expenses and Operating Profit

For selling, general and administrative expenses, we have created a plan by expense category, taking into account current trends and actual results. For the fiscal year ending March 31, 2027, we expect an increase in labor costs due to salary increases and other factors, and an increase in sales promotion expenses and advertising expenses to strengthen multifaceted sales promotion measures. Based on the above, SG&A expenses are projected to be ¥10,590 million (+8.6% year-on-year).

In addition, other income and other expenses are expected to be recorded, resulting in a projected operating profit of ¥4,140 million (-4.1% year-on-year).

5) Finance income, Finance expenses, Profit, Profit attributable to owners of parent

For finance income and expenses, the related gains and losses are calculated based on the planned values related to the balance of financial assets and borrowings.

Based on the above, financial expenses are expected to be ¥190 million (-23.7% year-on-year), affected by a decrease in interest expenses due to the prepayment of borrowings, and profit before tax is expected to be ¥3,950 million (-5.8% year-on-year), profit is expected to be ¥2,540 million (-14.0% year-on-year), and profit attributable to owners of the parent is expected to be ¥2,540 million (-14.1% year-on-year), respectively.

The financial results forecast is based on the information available at this time, and the actual financial results may differ due to various factors.

II. Basic Policy Regarding Selection of Accounting Standards

Our corporate group applies International Financial Reporting Standards (IFRS) since the fiscal year ended March 31, 2019 in order to enable the international comparison of financial information and improve convenience in the capital markets.

III. Consolidated Financial Statements and Significant Notes

1. Consolidated Statements of Financial Position

(Millions of yen)

	As of March 31, 2025	As of March 31, 2026
Assets		
Current assets		
Cash and cash equivalents	3,903	3,968
Trade and other receivables	2,490	2,679
Inventories	1,839	1,484
Biological assets	3,106	3,265
Income taxes receivable	14	17
Other current assets	146	273
Total current assets	11,501	11,688
Non-current assets		
Property, plant and equipment	17,784	17,698
Investment property	94	94
Goodwill and intangible assets	5,932	6,024
Right-of-use assets	210	219
Retirement benefit asset	307	158
Other financial assets	186	164
Deferred tax assets	1,785	1,594
Other non-current assets	65	42
Total non-current assets	26,367	25,997
Total assets	37,868	37,686

(Millions of yen)

	As of March 31, 2025	As of March 31, 2026
Liabilities		
Current liabilities		
Trade and other payables	2,886	2,726
Income taxes payable	1,370	880
Employee benefit accruals	2,512	2,256
Current portion of long-term borrowings	1,422	4,422
Lease liabilities	141	159
Provisions	193	217
Other financial liabilities	105	33
Other current liabilities	869	770
Total current liabilities	9,502	11,467
Non-current liabilities		
Borrowings	15,435	11,012
Lease liabilities	161	179
Deferred tax liabilities	152	150
Provisions	21	21
Other financial liabilities	69	84
Other non-current liabilities	0	0
Total non-current liabilities	15,841	11,448
Total liabilities	25,343	22,916
Equity		
Share capital	100	100
Capital surplus	(6,067)	(5,898)
Retained earnings	18,334	20,547
Treasury shares	(7)	(30)
Other components of equity	6	51
Total equity attributable to owners of parent	12,366	14,770
Non-controlling interests	159	-
Total equity	12,525	14,770
Total liabilities and equity	37,868	37,686

2. Consolidated Statements of Income and Comprehensive Income

(Consolidated Statements of Income)

(Millions of yen)

	Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026
Income		
Revenue	37,102	37,845
Gains arising from changes in fair value	16,037	15,604
Total income	53,139	53,449
Cost of sales (*1)	39,487	39,357
Gross profit	13,651	14,092
Selling, general and administrative expenses	9,550	9,757
Other income	88	170
Other expenses	1,769	186
Operating profit	2,419	4,319
Finance income	1	125
Finance expenses	246	249
Profit before tax	2,175	4,195
Income tax expense	679	1,240
Profit	1,496	2,954
Profit attributable to		
Owners of parent	1,502	2,958
Non-controlling interests	(6)	(3)
Earnings per share		
Basic earnings per share (Yen)	37.66	74.18
Diluted earnings per share (Yen)	37.65	74.18

Management believes that the information of “material costs, labor costs, etc.” facilitates comparison between the Group and competitors by users of financial statements. Therefore, we disclose the information voluntarily as a note in the summarized consolidated statements of income. “Material costs, labor costs, etc.” are the production costs of finished goods and purchasing costs of other goods sold by the Group, excluding the gains arising from changes in fair value recognized under IAS 41 “Agriculture”.

(*1) Components of cost of sales		
Material costs, labor costs, etc.	23,729	23,824
Gains arising from changes in fair value	15,758	15,532
Total	39,487	39,357

(Consolidated Statements of Comprehensive Income)

(Millions of yen)

	Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026
Profit	1,496	2,954
Other comprehensive income (After tax effect deduction)		
Items that will not be reclassified to profit or loss		
Remeasurements of defined benefit plans	(55)	(107)
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income	(13)	(0)
Total of items that will not be reclassified to profit or loss	(69)	(107)
Items that may be reclassified to profit or loss		
Exchange differences on translation of foreign operations	(4)	58
Total of items that may be reclassified to profit or loss	(4)	58
Total other comprehensive income (After tax effect deduction)	(73)	(49)
Comprehensive income	1,422	2,904
Comprehensive income attributable to		
Owners of parent	1,428	2,894
Non-controlling interests	(6)	10

3. Consolidated Statement of Changes in Equity

(Millions of yen)

	Share capital	Capital surplus	Retained earnings	Treasury shares	Other components of equity	Total equity attributable to owners of parent	Non-controlling interests	Total
Balance at beginning of period	100	(6,067)	17,405	(17)	25	11,446	164	11,610
Profit	-	-	1,502	-	-	1,502	(6)	1,496
Other comprehensive income	-	-	-	-	(73)	(73)	-	(73)
Comprehensive income	-	-	1,502	-	(73)	1,428	(6)	1,422
Purchase of own shares	-	-	-	(0)	-	(0)	-	(0)
Share-based remuneration transactions	-	(0)	-	10	-	9	-	9
Dividends of surplus	-	-	(518)	-	-	(518)	-	(518)
Changes in ownership interest in subsidiaries	-	-	-	-	-	-	-	-
Transfer from other components of equity to retained earnings	-	-	(54)	-	54	-	-	-
Other	-	-	-	-	-	-	1	1
Total	-	(0)	(573)	10	54	(508)	1	(507)
Balance at end of period	100	(6,067)	18,334	(7)	6	12,366	159	12,525
Profit	-	-	2,958	-	-	2,958	(3)	2,954
Other comprehensive income	-	-	-	-	(63)	(63)	14	(49)
Comprehensive income	-	-	2,958	-	(63)	2,894	10	2,904
Purchase of own shares	-	-	-	(32)	-	(32)	-	(32)
Share-based remuneration transactions	-	0	-	9	-	9	-	9
Dividends of surplus	-	-	(638)	-	-	(638)	-	(638)
Changes in ownership interest in subsidiaries	-	99	-	-	1	100	(170)	(69)
Transfer from other components of equity to retained earnings	-	-	(107)	-	107	-	-	-
Other	-	69	-	-	-	69	-	69
Total	-	169	(745)	(22)	108	(490)	(170)	(660)
Balance at end of period	100	(5,898)	20,547	(30)	51	14,770	-	14,770

4. Consolidated Statements of Cash Flows

(Millions of yen)

	Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026
Cash flows from operating activities		
Profit before tax	2,175	4,195
Depreciation and amortization	2,347	2,292
Impairment loss	1,599	98
Interest expenses	219	199
Loss (gain) on sale of fixed assets	0	(0)
Loss on retirement of fixed assets	118	53
Decrease (increase) in trade and other receivables	685	(146)
Decrease (increase) in inventories	(362)	361
Decrease (increase) in biological assets	(168)	(152)
Increase (decrease) in trade and other payables	(556)	(355)
Decrease (increase) in retirement benefit asset	(93)	(16)
Increase (decrease) in employee benefit liabilities	374	(256)
Other	358	(46)
Subtotal	6,696	6,226
Interest paid	(209)	(189)
Payments of commission for syndicate loan	(3)	-
Income taxes paid	(964)	(1,519)
Income taxes refund	-	17
Net cash provided by (used in) operating activities	5,519	4,534
Cash flows from investing activities		
Purchase of property, plant and equipment	(2,205)	(2,095)
Proceeds from sale of property, plant and equipment	1	0
Purchase of intangible assets	(18)	(53)
Other	(29)	62
Net cash provided by (used in) investing activities	(2,252)	(2,085)
Cash flows from financing activities		
Proceeds from short-term borrowings	2,000	1,900
Repayments of short-term borrowings	(2,000)	(1,900)
Repayments of long-term borrowings	(1,431)	(1,431)
Repayments of lease liabilities	(207)	(234)
Purchase of own shares	(0)	(32)
Dividends paid	(520)	(638)
Other	(0)	(69)
Net cash provided by (used in) financing activities	(2,159)	(2,406)
Effect of exchange rate changes on cash and cash equivalents	(2)	23
Net increase (decrease) in cash and cash equivalents	1,105	65
Cash and cash equivalents at beginning of period	2,797	3,903
Cash and cash equivalents at end of period	3,903	3,968

5. Notes to Summarized Consolidated Financial Statements

(Going Concern Assumptions)

Not applicable.

(Segment Information)

(1) Reportable segments

The Group's reportable segments are components of the Group for which separate financial information is available and regular evaluation by the Board of Directors, chief operating decision maker, is being performed in order to make decisions about resources to be allocated and to assess its performance. The mushroom business is listed as a reporting segment as the Group has a comprehensive strategy for products and services and is expanding its business activities. "Other" includes businesses that are not included in the reportable segment.

The Group aggregates Maitake business, Eryngii business, Buna-shimeji business, etc. as a reportable segment, "mushroom business," in terms of similarity of economic characteristics such as revenue trends, and the following features are all similar in this segment: (a) the nature of products and services, (b) the nature of the production processes, (c) the type of customers of the products and the services, (d) the method used to deliver the products or provide the services, and (e) the nature of regulatory environment.

Description of the reportable segment is as follows:

	Description of business
Mushroom business	Production and sales of Maitake, Eryngii, Buna-shimeji and other mushrooms

(2) Reportable segments information

The accounting methods of reportable business segments are the same as the Group's accounting policies. Figures reported as segment profit are based on operating profit reported in the summarized consolidated statements of income. Revenues from intersegment transactions are based on the current market prices.

Fiscal year ended March 31, 2025 (From April 1, 2024 to March 31, 2025)

(Millions of yen)

	Mushroom business	Others	Total	Adjustment items (*1)	Per consolidated financial statements
Revenue					
Revenue from external customers	36,779	322	37,102	-	37,102
Intersegment revenue	-	-	-	-	-
Total revenue	36,779	322	37,102	-	37,102
Segment profit (loss)	2,511	(77)	2,434	(14)	2,419
Finance income					1
Finance expenses					246
Profit before tax					2,175
Others					
Gains arising from changes in fair value included in total income	16,037	-	16,037	-	16,037
Gains arising from changes in fair value included in cost of sales	15,758	-	15,758	-	15,758
Depreciation and amortization	2,324	23	2,347	0	2,347
Impairment loss	1,599	-	1,599	-	1,599

(*1) Adjustment items for segment profit (loss) include corporate expenses that are not allocated to each business segment.

Fiscal year ended March 31, 2026 (From April 1, 2025 to March 31, 2026)

(Millions of yen)

	Mushroom business	Others	Total	Adjustment items (*1)	Per consolidated financial statements
Revenue					
Revenue from external customers	37,471	373	37,845	-	37,845
Intersegment revenue	-	-	-	-	-
Total revenue	37,471	373	37,845	-	37,845
Segment profit (loss)	4,384	(98)	4,286	32	4,319
Finance income					125
Finance expenses					249
Profit before tax					4,195
Others					
Gains arising from changes in fair value included in total income	15,604	-	15,604	-	15,604
Gains arising from changes in fair value included in cost of sales	15,532	-	15,532	-	15,532
Depreciation and amortization	2,271	20	2,292	0	2,292
Impairment loss	98	-	98	-	98

(*1) Adjustment items for segment profit (loss) include corporate expenses that are not allocated to each business segment.

(Earnings per Share)

Calculation of basic earnings per share and diluted earnings per share are described below.

	(Unit)	Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026
Basic earnings per share			
Profit attributable to owners of parent	(Millions of yen)	1,502	2,958
Profit not attributable to common shareholders of parent	(Millions of yen)	-	-
Profit used for calculation of basic earnings per share	(Millions of yen)	1,502	2,958
Average number of common shares during the period	(Thousand shares)	39,891	39,876
Basic earnings per share	(Yen)	37.66	74.18
Diluted earnings per share			
Profit used for calculation of basic earnings per share	(Millions of yen)	1,502	2,958
Adjustment	(Millions of yen)	-	-
Profit used for calculation of diluted earnings per share	(Millions of yen)	1,502	2,958
Average number of common shares during the period	(Thousand shares)	39,891	39,876
Increase of shares due to restricted stock compensation plan	(Thousand shares)	5	4
Average number of common shares during the period after dilution	(Thousand shares)	39,897	39,880
Diluted earnings per share	(Yen)	37.65	74.18

(Significant Subsequent Events)

Not applicable.